|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-12-2
|
|
pubmed:abstractText |
Selection and persistence of non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated mutations during treatment interruptions (TIs) has been attributed to the long plasma half-life of these drugs. However, little is known about the contribution of variable NNRTI plasma levels before a TI. We evaluated the selection of NNRTI-related mutations and the coefficient of variation of NNRTI plasma concentrations during different TI periods.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1359-6535
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
945-51
|
|
pubmed:meshHeading |
pubmed-meshheading:19043929-Anti-HIV Agents,
pubmed-meshheading:19043929-Benzoxazines,
pubmed-meshheading:19043929-CD4 Lymphocyte Count,
pubmed-meshheading:19043929-DNA, Viral,
pubmed-meshheading:19043929-Drug Administration Schedule,
pubmed-meshheading:19043929-Drug Resistance, Viral,
pubmed-meshheading:19043929-Drug Therapy, Combination,
pubmed-meshheading:19043929-Genotype,
pubmed-meshheading:19043929-HIV Infections,
pubmed-meshheading:19043929-HIV Reverse Transcriptase,
pubmed-meshheading:19043929-HIV-1,
pubmed-meshheading:19043929-Humans,
pubmed-meshheading:19043929-Mutation,
pubmed-meshheading:19043929-Nevirapine,
pubmed-meshheading:19043929-Proviruses,
pubmed-meshheading:19043929-RNA, Viral,
pubmed-meshheading:19043929-Reverse Transcriptase Inhibitors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
|
|
pubmed:affiliation |
IrsiCaixa Foundation, Badalona, Spain. ldarwich@irsicaixa.es
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
